Optimization of Tuberculosis Intradermal Skin Test

NACompletedINTERVENTIONAL
Enrollment

59

Participants

Timeline

Start Date

September 30, 2011

Primary Completion Date

June 30, 2012

Study Completion Date

April 30, 2013

Conditions
Healthy Volunteers
Interventions
DEVICE

Medical device : micro-needle BD 1.5 mm 30G drug:Tubertest® : tuberculin (purified protein derivative)

"2 intradermal injections are performed on each arm/bottom of the subject:~* 1 intradermal injection of Tuberculin (5UI)~* 1 intradermal injection of saline solution using Manthoux method or BD micro-needle. the method of injection is randomized: left or right"

DEVICE

medical device: lance 26G X 16mm drug: Tubertest® : tuberculin (purified protein derivative)

"2 intradermal injections are performed on each arm/bottom of the subject:~* 1 intradermal injection of Tuberculin (5UI)~* 1 intradermal injection of saline solution using Manthoux method or BD micro-needle. the method of injection is randomized: left or right"

Trial Locations (1)

69495

Unité de Recherche Clinique en Immunologie Lyon Sud (URCI-LS) et Service d'Immunologie clinique et allergologie-Centre Hospitalier Lyon Sud -Hospices Civils de Lyon, Pierre-Bénite

All Listed Sponsors
lead

Hospices Civils de Lyon

OTHER

NCT01611844 - Optimization of Tuberculosis Intradermal Skin Test | Biotech Hunter | Biotech Hunter